Novo Nordisk reports positive clinical data for Victoza

Novo Nordisk has announced new clinical evidence underlining the safety and efficacy of its drug Victoza in the treatment of type 2 diabetes.

The company has reported data from the clinical trial LIRA-SWITCH, which aimed to explore the benefits of switching to treatment with Victoza from an established alternative therapy.

It was shown that switching to Victoza provided superior blood glucose level reductions compared to continuing with with the other treatment in adults with type 2 diabetes, with these patients also experiencing greater body weight reductions.

The 26-week trial involved 407 adults with type 2 diabetes who were not achieving adequate glycaemic control on the older treatment regime.

Study investigator Dr Maximo Maislos said: "These findings are valuable as there is limited clinical evidence to guide treatment strategy when people with type 2 diabetes are uncontrolled on second-line therapy."

The drug previously demonstrated its cost-effectiveness benefits in a UK study of type 2 diabetes patients, the results of which were made available last November.